tiprankstipranks
Advertisement
Advertisement

DYN Stock Latest News

Dyne Therapeutics price target lowered to $45 from $47 at Morgan Stanley
The FlyDyne Therapeutics price target lowered to $45 from $47 at Morgan Stanley
11h ago
DYN
Dyne Therapeutics reports Q2 EPS ($1.08), consensus (75c)
PremiumThe Fly
Dyne Therapeutics reports Q2 EPS ($1.08), consensus (75c)
2d ago
DYN
Dyne Therapeutics: Buy Rating Reiterated as FORCE Platform Expands; $47 Price Target Maintained
PremiumRatings
Dyne Therapeutics: Buy Rating Reiterated as FORCE Platform Expands; $47 Price Target Maintained
3d ago
DYN
Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial
PremiumThe Fly
Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial
4d ago
DYN
Dyne Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Dyne Therapeutics initiated with an Overweight at Cantor Fitzgerald
9d ago
DYN
Dyne Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe FlyDyne Therapeutics initiated with an Overweight at Cantor Fitzgerald
9d ago
DYN
Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway
Premium
Company Announcements
Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway
9d ago
8K
DYN
Midday Fly By: AT&T reports Q2 beat, AMD invests $5B in Anthropic
Premium
The Fly
Midday Fly By: AT&T reports Q2 beat, AMD invests $5B in Anthropic
9d ago
T
PM
Dyne Therapeutics 18.3M share Spot Secondary priced at $20.50
PremiumThe Fly
Dyne Therapeutics 18.3M share Spot Secondary priced at $20.50
10d ago
DYN
Closing Bell Movers: Finward jumps after First Financial deal
PremiumThe Fly
Closing Bell Movers: Finward jumps after First Financial deal
10d ago
ALK
DYN
Dyne Therapeutics $300M Spot Secondary; price range $20.00-$21.50
PremiumThe Fly
Dyne Therapeutics $300M Spot Secondary; price range $20.00-$21.50
10d ago
DYN
Dyne Therapeutics announces $300M common stock offering
PremiumThe Fly
Dyne Therapeutics announces $300M common stock offering
10d ago
DYN
Citi sees intensifying competition for Sarepta from Dyne Therapeutics
PremiumThe FlyCiti sees intensifying competition for Sarepta from Dyne Therapeutics
11d ago
DYN
SRPT
Dyne Therapeutics Advances DYNE-251 With FDA Priority Review
Premium
Company Announcements
Dyne Therapeutics Advances DYNE-251 With FDA Priority Review
12d ago
8K
DYN
Dyne Therapeutics announces FDA acceptance of zeleciment rostudirsen BLA
Premium
The Fly
Dyne Therapeutics announces FDA acceptance of zeleciment rostudirsen BLA
12d ago
DYN
Dyne Therapeutics initiated with a Buy at TD Cowen
PremiumThe Fly
Dyne Therapeutics initiated with a Buy at TD Cowen
1M ago
DYN
Joseph Thome Initiates Buy on Dyne Therapeutics, Citing Late-Stage Pipeline Strength and Multi-Billion-Dollar Peak Sales Potential
PremiumRatings
Joseph Thome Initiates Buy on Dyne Therapeutics, Citing Late-Stage Pipeline Strength and Multi-Billion-Dollar Peak Sales Potential
1M ago
DYN
Dyne Therapeutics Names Barry Greene Independent Board Director
PremiumCompany Announcements
Dyne Therapeutics Names Barry Greene Independent Board Director
1M ago
8K
DYN
Dyne Therapeutics Expands Hercules Debt Facility for Flexibility
PremiumCompany Announcements
Dyne Therapeutics Expands Hercules Debt Facility for Flexibility
1M ago
8K
DYN
Dyne Therapeutics Expands Share Authorization After Stockholder Approvals
PremiumCompany AnnouncementsDyne Therapeutics Expands Share Authorization After Stockholder Approvals
2M ago
8K
DYN
Acting FDA head vows to block political interference, Endpoint News says
Premium
The Fly
Acting FDA head vows to block political interference, Endpoint News says
2M ago
AZN
BMY
Analyst Reiterates Buy on Dyne Therapeutics, Maintains $44 Price Target on De-Risked Late-Stage Pipeline and Regulatory Momentum
Premium
Ratings
Analyst Reiterates Buy on Dyne Therapeutics, Maintains $44 Price Target on De-Risked Late-Stage Pipeline and Regulatory Momentum
2M ago
DYN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >